OnKure Announces Closing of Merger with Reneo Pharmaceuticals and Concurrent Private Placement of $65 Million
October 04, 2024 16:57 ET
|
Reneo Pharmaceuticals, Inc.; OnKure Therapeutics, Inc.
OnKure Announces Closing of Merger with Reneo Pharmaceuticals
Reneo Pharmaceuticals Announces Stockholder Approval of Merger with OnKure
October 02, 2024 20:20 ET
|
Reneo Pharmaceuticals, Inc.
– Combined company to trade on Nasdaq under ticker “OKUR” – Reneo announces 1-for-10 reverse split of common stock IRVINE, Calif., Oct. 02, 2024 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc....
Reneo Pharmaceuticals Reports Second Quarter 2024 Financial Results
August 13, 2024 07:35 ET
|
Reneo Pharmaceuticals, Inc.
IRVINE, Calif., Aug. 13, 2024 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM), a pharmaceutical company historically focused on the development and commercialization of therapies for...
Reneo Pharmaceuticals and OnKure Announce Proposed Merger
May 13, 2024 07:35 ET
|
Reneo Pharmaceuticals, Inc.; OnKure, Inc
Merger to create a Nasdaq-listed, clinical-stage biopharmaceutical company focused on advancing OnKure’s portfolio of novel precision medicines in oncology Combined company is expected to have...
Reneo Pharmaceuticals Reports First Quarter 2024 Financial Results
May 07, 2024 07:35 ET
|
Reneo Pharmaceuticals, Inc.
Reneo Pharmaceuticals Reports First Quarter 2024 Financial Results
Reneo Pharmaceuticals Reports Fourth Quarter And Full Year 2023 Financial Results And Business Update
March 28, 2024 07:35 ET
|
Reneo Pharmaceuticals, Inc.
IRVINE, Calif., March 28, 2024 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM), a pharmaceutical company historically focused on the development and commercialization of therapies for...
Reneo Pharmaceuticals Announces Results from Pivotal STRIDE Study of Mavodelpar in Primary Mitochondrial Myopathies (PMM)
December 14, 2023 09:05 ET
|
Reneo Pharmaceuticals, Inc.
The STRIDE study did not meet its primary or secondary efficacy endpoint The company to suspend mavodelpar development and implement a workforce reduction IRVINE, Calif., Dec. 14, 2023 (GLOBE...
Reneo Pharmaceuticals Reports Third Quarter 2023 Financial Results
November 13, 2023 07:35 ET
|
Reneo Pharmaceuticals, Inc.
IRVINE, Calif., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM), a clinical-stage pharmaceutical company focused on the development and commercialization of therapies...
Reneo Pharmaceuticals to Participate in Upcoming Investor Conferences
November 02, 2023 07:50 ET
|
Reneo Pharmaceuticals, Inc.
IRVINE, Calif., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies...
Reneo Pharmaceuticals Announces Poster Presentation at Upcoming Scientific Meetings
October 25, 2023 07:50 ET
|
Reneo Pharmaceuticals, Inc.
IRVINE, Calif., Oct. 25, 2023 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies...